Blau Farmacêutica

What Blau Farmacêutica does

Blau Farmacêutica S/A is a publicly traded Brazilian pharmaceutical company (B3 ticker BLAU3), founded in 1987 and headquartered in Cotia, São Paulo. The company manufactures high-complexity and essential hospital medicines, with a strategic focus on biologics, biosimilars, and oncology products. Its technology platform spans biotechnology and pharmaceutical manufacturing, anchored by the Inventta R&D subsidiary, which has produced what Blau describes as the first fully domestically developed pembrolizumab biosimilar in Brazil — a high-complexity monoclonal antibody immunotherapy supported by ANVISA GMP certification for active pharmaceutical ingredient production.

Blau operates a B2B and B2G go-to-market model, distributing products directly to hospitals and healthcare providers through enterprise field sales, and participating in public tender processes to supply the Brazilian public healthcare system (SUS). Revenue is generated primarily through one-time sales of pharmaceutical products, with potential future licensing and royalty income from biosimilar approvals in Brazil (target 2028), the US (2029), and Europe (2031). The portfolio is diversified across the core Blau hospital medicines line, the acquired Bergamo oncology and biologics brand (purchased from Amgen for US$28 million in October 2022), the Blau Aesthetics sub-brand, and the Inventta R&D subsidiary.

In Q1 2026, Blau reported revenue of BRL 435 million, up 17% year-over-year, with a record 41.4% gross margin and a zero-leverage balance sheet supported by BRL 542 million in cash. The company employs between 1,001 and 5,000 people and operates in seven countries across Latin America and the United States. Customer concentration is oriented toward the hospital segment, with the pembrolizumab bios representing a BRL 5 billion domestic market opportunity and potential access to more than 50,000 patients annually.

Name

Blau Farmacêutica

Legal name

Blau Farmacêutica S/A

Website

https://blau.com.br

Company type

Public

Founded year

1987

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Blau Farmacêutica is a publicly traded Brazilian pharmaceutical manufacturer producing high-complexity hospital medicines, biologics, and biosimilars — including a domestically developed pembrolizumab biosimilar — for healthcare providers and public health systems across Latin America and the US.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Monoclonal Antibody (mAb) Biosimilars (HLAAAHAA)

akta.pro secondary industries

Oncology Biosimilars (HLAAAHAG), Generic Hospital & Institutional Products (HLAIABAL)

Keywords

• Hospital pharmaceuticals
• Biosimilar development
• Oncology medicines
• Biological medicines
• Pharmaceutical manufacturing

Headquarters

HQ city

Barro Branco

HQ country

Brazil

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales

Revenue model

1. Pharmaceutical product sales: Revenue generated from manufacturing and selling high-complexity pharmaceutical and hospital products including biologics and biosimilars to healthcare providers and public healthcare systems.
2. Biosimilar licensing: Potential future revenue from licensing biosimilar products upon regulatory approvals in Brazil (2028), US (2029), and Europe (2031).

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

Blau Farmacêutica manufactures and sells high-complexity hospital pharmaceuticals and essential medicines for the Latin American healthcare market, with a portfolio that includes biologics, biosimilars, oncology treatments, and aesthetic products. Through its Bergamo subsidiary it serves oncology and biological-medicines channels, and through its Inventta R&D arm it is developing a domestically produced pembrolizumab biosimilar, the first fully end-to-end developed monoclonal antibody in Brazil with ANVISA GMP certification for the API.

Product overview

Blau Farmacêutica operates as a unified pharmaceutical platform with a diversified portfolio spanning high-complexity hospital medicines, oncology and biological medicines, and aesthetics products. The company structure includes its main Blau Farmacêutica brand, the acquired Bergamo brand from Amgen (specializing in oncology and biosimilars), the dedicated R&D subsidiary Inventta focused on biotechnology innovation, and the Blau Aesthetics sub-brand. The company's Q1 2026 results demonstrate strong hospital segment performance with 17% revenue growth, while its landmark pembrolizumab biosimilar development positions Brazil among countries capable of producing complex monoclonal antibodies at industrial scale.

Differentiator

Problem solved

Functional benefit

Brands

• Inventta: Research and development subsidiary (PD&I)
• Bergamo

Products and services

• Pembrolizumab Biosimilar
• Hospital Medicines Portfolio

Quantifiable outcome

• 17% year-over-year revenue growth to BRL 435 million in Q1 2026
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• AmgencoreOthers · 31 October 2022Acquisition of 100% of Laboratório Químico Farmacêutico Bergamo from Amgen for US$ 28 million. This strategic acquisition expanded Blau's presence in the oncology and biological medicines markets and increased production capacity.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Eurofarma Laboratórios: One of the largest Brazilian pharmaceutical companies producing branded, generic, and hospital pharmaceutical products across Latin America. Directly comparable to Blau as a vertically integrated Brazilian pharma with hospital segment focus and biosimilar/biologic ambitions.
• Cristália: Privately held Brazilian pharmaceutical company specializing in high-complexity hospital medicines, anesthetics, and biological products. Directly comparable to Blau's hospital and high-complexity focus with domestic manufacturing emphasis.
• EMS Pharma: Largest Brazilian pharmaceutical company by prescriptions, with a broad portfolio including generics, branded, and hospital products. Comparable to Blau as a domestic pharma leader with hospital channel exposure and investment in biological products.
• Hypera Pharma: Largest Brazilian pharma company by market cap, with diversified branded, generic, and OTC portfolio. Comparable to Blau as a publicly-traded Brazilian pharma peer with hospital channel exposure and growth via M&A (Hyperapharma/Neo Química).
• Biolab Farmacêutica: Brazilian pharmaceutical company focused on prescription drugs, hospital medicines, and dermatology. Comparable to Blau in domestic pharma scale with hospital channel concentration and investment in specialty/biosimilar products.
• Aché Laboratórios: Major Brazilian pharmaceutical manufacturer with branded and generic products across multiple therapeutic areas including oncology and hospital medicines. Comparable to Blau in domestic pharma scale, hospital segment focus, and biologic/biosimilar development efforts.

Broad incumbents

• Amgen: Global biotechnology leader and originator of multiple biologics. Comparable as the prior owner of Bergamo (sold to Blau in 2022) and as a global biosimilar competitor with deep expertise in mAb manufacturing and oncology.

Emerging players

• Biocon: India-based global biopharmaceutical company with one of the largest biosimilars portfolios globally, including oncology biosimilars (trastuzumab, bevacizumab, pegfilgrastim). Comparable to Blau as a biosimilar developer targeting emerging and developed markets.
• Celltrion: South Korean biopharmaceutical company with leading global biosimilar portfolio including infliximab, rituximab, trastuzumab, and bevacizumab. Comparable to Blau as a global biosimilar competitor targeting oncology and immunology indications.
• Samsung Bioepis: Joint venture between Samsung Biologics and Biogen developing biosimilars including oncology antibodies. Comparable to Blau as a biosimilar competitor with commercial scale and FDA/EMA approvals for multiple mAb biosimilars.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCR3EHDD_Cfc7I9EaduCUFog
• Facebookfacebook.com/blaufarmaceutica
• LinkedInlinkedin.com/company/blausiegel
• Instagraminstagram.com/blaufarmaceutica

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Blau Farmacêutica